{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T14:55:35Z","timestamp":1770908135949,"version":"3.50.1"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":544,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T00:00:00Z","timestamp":1713484800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Merck Sharp & Dohme LLC"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Patients with HFrEF and worsening HF events (WHFE) are at particularly high risk and urgently need disease-modifying therapy. CHART-HF assessed treatment patterns and reasons for medication decisions among HFrEF patients with and without WHFE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>CHART-HF collected retrospective electronic medical records of outpatients with HF and EF &amp;lt; 45% between 2017\u20132019 from a nationwide panel of 238 cardiologists (458 patients) and the Geisinger Health System (GHS) medical record (1000 patients). The index visit in the WHFE cohort was the first outpatient cardiologist visit \u22646 months following the WHFE, and in the reference cohort was the last visit in a calendar year without WHFE. Demographic characteristics were similar between patients with and without WHFE in both the nationwide panel and GHS. In the nationwide panel, the proportion of patients with versus without WHFE receiving \u226550% of guideline-recommended dose on index visit was 35% versus 40% for beta blocker, 74% versus 83% for ACEI\/ARB\/ARNI, and 48% versus 49% for MRA. The proportion of patients receiving \u226550% of guideline-recommended dose was lower in the GHS: 29% versus 34% for beta-blocker, 16% versus 31% for ACEI\/ARB\/ARNI, and 18% versus 22% for MRA. For patients with and without WHFE, triple therapy on index date was 42% and 44% of patients from the nationwide panel, and 14% and 17% in the GHS. Comparing end of index clinic visit with 12-month follow-up in the GHS, the proportion of patients on no GDMT increased from 14% to 28% in the WHFE cohort and from 14 to 21% in the non-WHFE group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Major gaps in use of GDMT, particularly combination therapy, remain among US HFrEF patients. These gaps persist during longitudinal follow-up and are particularly large among patients with recent WHFE.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.14805","type":"journal-article","created":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T08:03:31Z","timestamp":1713513811000},"page":"1932-1946","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Treatment Patterns of Patients with Worsening Heart Failure with Reduced Ejection Fraction"],"prefix":"10.1093","volume":"11","author":[{"given":"Stephen J.","family":"Greene","sequence":"first","affiliation":[{"name":"Duke Clinical Research Institute , Durham, NC ,","place":["USA"]},{"name":"Division of Cardiology, Duke University School of Medicine , Durham, NC ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna K.","family":"Gaggin","sequence":"additional","affiliation":[{"name":"Harvard Medical School , Boston, MA ,","place":["USA"]},{"name":"Division of Cardiology, Massachusetts General Hospital , Boston, MA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mo","family":"Zhou","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc. , Boston, MA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lori D.","family":"Bash","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. , Rahway, NJ ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominik","family":"Lautsch","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. , Rahway, NJ ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Djatche","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. , Rahway, NJ ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Song","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc. , Boston, MA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Signorovitch","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc. , Boston, MA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andra S.","family":"Stevenson","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. , Rahway, NJ ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert O.","family":"Blaustein","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc. , Rahway, NJ ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Mississippi Medical Center , Jackson, MS ,","place":["USA"]},{"name":"Baylor Scott and White Research Institute , Dallas, TX ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,4,19]]},"reference":[{"key":"2026012113132895100_ehf214805-bib-0001","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.011","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026012113132895100_ehf214805-bib-0002","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2026012113132895100_ehf214805-bib-0003","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.jacc.2018.11.049","article-title":"Clinical course of patients with worsening heart failure with reduced ejection fraction","volume":"73","author":"Butler","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026012113132895100_ehf214805-bib-0004","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1007\/s12325-020-01456-1","article-title":"Clinical and economic burden of chronic heart failure and reduced ejection fraction following a worsening heart failure event","volume":"37","author":"Butler","year":"2020","journal-title":"Adv Ther"},{"key":"2026012113132895100_ehf214805-bib-0005","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1002\/ejhf.2727","article-title":"Outpatient versus inpatient intravenous diuretic therapy for heart failure in the United States","volume":"24","author":"Greene","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026012113132895100_ehf214805-bib-0006","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.cardfail.2021.06.019","article-title":"Representativeness of the VICTORIA trial population in clinical practice: analysis of the PINNACLE registry","volume":"27","author":"Butler","year":"2021","journal-title":"J Card Fail"},{"key":"2026012113132895100_ehf214805-bib-0007","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.cardfail.2021.05.017","article-title":"Patient-centered outcomes in HFrEF following a worsening heart failure event: a survey analysis","volume":"27","author":"Dunbar","year":"2021","journal-title":"J Card Fail"},{"key":"2026012113132895100_ehf214805-bib-0008","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1080\/13696998.2021.1922195","article-title":"Quality outcomes, healthcare resource utilization and costs in Medicare patients with chronic heart failure with reduced ejection fraction with and without a worsening event","volume":"24","author":"Mentz","year":"2021","journal-title":"J Med Econ"},{"key":"2026012113132895100_ehf214805-bib-0009","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1016\/j.jacc.2019.02.015","article-title":"Titration of medical therapy for heart failure with reduced ejection fraction","volume":"73","author":"Greene","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026012113132895100_ehf214805-bib-0010","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1001\/jama.2021.20739","article-title":"Contextualizing risk among patients with heart failure","volume":"326","author":"Greene","year":"2021","journal-title":"JAMA"},{"key":"2026012113132895100_ehf214805-bib-0011","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ahj.2022.05.016","article-title":"Contemporary outpatient Management of patients with worsening heart failure with reduced ejection fraction: rationale and design of the CHART-HF study","volume":"251","author":"Greene","year":"2022","journal-title":"Am Heart J"},{"key":"2026012113132895100_ehf214805-bib-0012","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1002\/ejhf.2874","article-title":"Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology","volume":"25","author":"Metra","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026012113132895100_ehf214805-bib-0013","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.jacc.2022.11.023","article-title":"Worsening heart failure: nomenclature, epidemiology, and future directions: JACC review topic of the week","volume":"81","author":"Greene","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026012113132895100_ehf214805-bib-0014","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1007\/s12325-018-0784-z","article-title":"Comparative effectiveness of nab-paclitaxel plus gemcitabine vs FOLFIRINOX in metastatic pancreatic cancer: a retrospective nationwide chart review in the United States","volume":"35","author":"Kim","year":"2018","journal-title":"Adv Ther"},{"key":"2026012113132895100_ehf214805-bib-0015","doi-asserted-by":"publisher","first-page":"300","DOI":"10.3747\/co.26.4485","article-title":"Effectiveness of first-line treatments in metastatic squamous non-small-cell lung cancer","volume":"26","author":"Levy","year":"2019","journal-title":"Curr Oncol"},{"key":"2026012113132895100_ehf214805-bib-0016","doi-asserted-by":"publisher","first-page":"929","DOI":"10.18553\/jmcp.2018.17337","article-title":"Antiepileptic drug titration and related health care resource use and costs","volume":"24","author":"Fishman","year":"2018","journal-title":"J Manag Care Spec Pharm"},{"key":"2026012113132895100_ehf214805-bib-0017","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.jchf.2020.01.012","article-title":"A machine learning approach to management of heart failure populations","volume":"8","author":"Jing","year":"2020","journal-title":"JACC Heart Fail"},{"key":"2026012113132895100_ehf214805-bib-0018","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1016\/j.mayocp.2020.03.035","volume-title":"Mayo Clin Proc","author":"Secora","year":"2020"},{"key":"2026012113132895100_ehf214805-bib-0019","doi-asserted-by":"publisher","first-page":"e3557","DOI":"10.1210\/clinem\/dgaa490","article-title":"Five-year estimated glomerular filtration rate in patients with hypoparathyroidism treated with and without rhPTH (1\u201384)","volume":"105","author":"Chen","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2026012113132895100_ehf214805-bib-0020","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/ejhf.1351","article-title":"Medication dosing for heart failure with reduced ejection fraction - opportunities and challenges","volume":"21","author":"Marti","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012113132895100_ehf214805-bib-0021","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry","volume":"72","author":"Greene","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026012113132895100_ehf214805-bib-0022","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1002\/ejhf.2252","article-title":"Treatment patterns and clinical outcomes among patients&lt;65 years with a worsening heart failure event","volume":"23","author":"Butler","year":"2021","journal-title":"Eur J Heart Fail"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/11\/4\/1932\/64526617\/eschf_11_4_1932.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/11\/4\/1932\/64526617\/eschf_11_4_1932.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:15:12Z","timestamp":1769019312000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/11\/4\/1932\/8271145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,19]]},"references-count":22,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4,19]]},"published-print":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.14805","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8]]},"published":{"date-parts":[[2024,4,19]]},"assertion":[{"value":"2023-09-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}